New research reveals shifting identities of global fishing fleet to help bolster fisheries management
18 janv. 2023 15h27 HE
|
Global Fishing Watch
WASHINGTON, D.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- A new study published today in Science Advances combines a decade’s worth of satellite vessel tracking data with identification information from...
Emerging technology gives first ever global view of hidden vessels
08 juin 2022 00h01 HE
|
Global Fishing Watch
Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) -- Global Fishing Watch has developed and publicly released the first ever global map of previously undetected dark fleets, or vessels that do not...
OmniMesh Taps AIS for Cybersecurity in its Content Delivery Solutions
24 sept. 2019 10h21 HE
|
OmniMesh
Addition of world-class, defense-grade security assures privacy and security in content management Syracuse, NY, Sept. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- OmniMesh, a leader in...
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
06 sept. 2019 09h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth...
DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
03 sept. 2019 16h15 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor...
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 16h35 HE
|
DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II...
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
12 août 2019 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference,...
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
08 août 2019 16h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on...
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
19 juin 2019 16h04 HE
|
DiaMedica Therapeutics Inc.
Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney...
DiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019
22 mai 2019 09h30 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor...